Centessa Pharmaceuticals Proposes $150M Public Offering of American Depositary Shares

BOSTON and LONDON, Sept. 11, 2024 – Centessa Pharmaceuticals plc (Nasdaq: CNTA), a company engaged in clinical-stage pharmaceutical development, announced the launch of an underwritten public offering worth $150 million in American Depositary Shares (ADSs). Each ADS represents one ordinary share of the company and all of them are being offered by Centessa. Additionally, the company plans to provide underwriters with a 30-day option to purchase up to an extra $22.5 million worth of ADSs, subject to market conditions and other variables. There is no guarantee on the completion, size, or terms of this offering.

Centessa has appointed several notable financial institutions as joint book-running managers for this offering, including Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets. The ADSs will be offered under a registration statement on Form S-3, filed with the United States Securities and Exchange Commission (SEC) on September 11, 2024, and it became automatically effective upon filing. Relevant documents such as the preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC’s official website.

For those interested in obtaining copies of these documents, they can be requested from the respective departments of the involved financial institutions, including Goldman Sachs, Leerink Partners, Evercore, Guggenheim Securities, and BMO Capital Markets. Each institution has provided specific contact information for prospective investors to request these documents. 

Centessa Pharmaceuticals is a clinical-stage company focused on discovering and developing transformational medicines. Their primary programs include treatments for hemophilia, orexin agonists for narcolepsy and other sleep-wake disorders, and an immuno-oncology program utilizing their proprietary LockBody® technology platform. The company is driven by the belief that each of its programs has the potential to shift current treatment paradigms and establish new standards of care.

This announcement does not serve as an offer to sell or a solicitation to buy these securities in jurisdictions where such actions would be illegal before proper registration or qualification under the local securities laws.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!